Aktis Oncology ($AKTS) Insider Trading & Smart Money Activity

Aktis Oncology, Inc. · Biotechnology · Latest filing Sep 23, 2026

Aktis Oncology, Inc. ($AKTS) has 1 insider trade, 4 13F position changes and 1 analyst rating on file. In the last 12 months on the open market, no insider bought and 1 insider sold ($258.62K), net -$258.62K.

Insider buyers (12 mo): 0
Insider sellers (12 mo): 1
Net insider $ (12 mo): -$258.62K
Congress trades (12 mo): 0
13F moves on file: 4
Analyst ratings on file: 1

AKTS insider buying and selling by quarter

Quarter	Insider sales	Congress buys / sales	13F added / cut
Q1 2026	0	0 / 0	0 / 0
Q2 2026	0	0 / 0	4 / 0
Q3 2026	1 · $258.62K	0 / 0	0 / 0
Q4 2026	0	0 / 0	0 / 0

Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.

All AKTS insider, congress, 13F and analyst activity

Date	Source	Who	Action	Shares	Value / amount	1W	1M	Story
Sep 23, 2026	Insider	Czibere AkosChief Medical Officer	Sell (Open-market sale) 10b5-1	12.50K sh	$258.62K	-1.3%		—
Jun 16, 2026	Analyst	Raymond James	Reiterates to buy		PT $40	+19.4%	+10.6%	Read
May 15, 2026	13F	Rtw Investments	New	+1.59M sh	$33.48M	+4.0%	+5.8%	Read
May 15, 2026	13F	Rtw Investments	New	+1.59M sh	$52.27M	+4.0%	+5.8%	Read
May 15, 2026	13F	Baker Bros. Advisors	New	+996.35K sh	$20.95M	+4.0%	+5.8%	—
May 15, 2026	13F	Baker Bros. Advisors	New	+996.35K sh	$32.71M	+4.0%	+5.8%	Read

1W / 1M / 6M = how AKTS moved from the trade or filing date.

Insider trading in AKTS: who is buying and selling

Insider	Role	Trades	Open-market net	Shares held	Last trade
Czibere Akos	Chief Medical Officer	1	-$258.62K		Sep 23, 2026

Institutions moving AKTS (13F)

Analyst ratings on AKTS

Date	Firm	Action	Rating	Price target	1W	1M	6M	Story
Jun 16, 2026	Raymond James	Reiterates	buy	$40	+19.4%	+10.6%		Read

Frequently asked questions

Are AKTS insiders buying or selling?

Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 1 insider made 1 open-market sale worth $258.62K, a net -$258.62K.

What is the latest insider trade in AKTS?

Czibere Akos, Chief Medical Officer filed a sell (open-market sale) of 12.50K sh worth $258.62K on Sep 23, 2026.

Which institutions changed their AKTS positions?

Recent 13F filers moving the stock include Rtw Investments and Baker Bros. Advisors.

Other biotechnology stocks

All stocks Insider cluster buys Top insider purchases Congress 13F institutions

Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.

Get trade alerts by text